Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Recruiting Phase 2 Interventional Study
Sickle Cell Disease Vaso-Occlusive Pain Episode in Sickle Cell Disease Ketamine Infusion Pain Management Vaso-Occlusive Crises
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
5 – 20
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
120 (estimated)
Sponsor
Mohsen Saidinejad · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of c…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Between the ages 5-20 years * Diagnosed sickle cell disease. Homozygous (HbSS) or heterozygous (HbSC, HbSBetaThal Plus or Zero) will be included. * Presenting with VOE pain, requiring IV pain medication. * First dose of analgesic medication is given before patient approached f…
Contacts

Cynthia Luo, MD

310-222-2345

cluo2@dhs.lacounty.gov

CONTACT

Mohsen Saidinejad, MD

moh@emedharbor.edu

CONTACT